Skip to content
Home/Companies/Biotech/GAMUT Therapeutics

GAMUT Therapeutics

Biotech·France·Exited 2021·Held 1yr
Entry
2020
Hold
1yr
Exit
2021

Who owns GAMUT Therapeutics?

GAMUT Therapeutics is a French Biotech company, now owned by SparingVision, which acquired it in 2021 from AdBio Partners.

Hand-verified · updated 2026-07-07

Open JSON · CC-BY
AdBio Partners
Investor
AdBio Partners
AFB Seed-Fund · 2017 · VC

Key facts

HQFrance
SectorBiotech
StatusAcquired
Exit Type
Trade Sale
Buyer
SparingVision
Exit Year
2021

More from AFB Seed-Fund

Other portfolio companies in the same fund.

Alderaan Biotechnology
Active
BiotechFrance· 2020
ARTHEx Biotech
ARTHEx Biotech
Active
BiotechSpain· 2020
Kalsiom
Kalsiom
Active
BiotechFrance· 2020
Wellium
Active
HealthcareFrance· 2020
Agomab Therapeutics
Agomab Therapeutics
Exited 2026
BiotechBelgium· 2019
to Nasdaq (IPO)
SparingVision
SparingVision
Active
BiotechFrance· 2019

More PE-backed in Biotech

Comparable biotech deals from other GPs.

Abbisko Healthcare
Active
The Carlyle GroupChina
Adagene
Active
General AtlanticChina
Advanced Cell Diagnostics
Active
Summit PartnersUS
Akero Therapeutics
Akero Therapeutics
Active
General AtlanticUS
Aldevron
Aldevron
Active
TA AssociatesUS
Alloy Therapeutics
Alloy Therapeutics
Active
Mubadala CapitalUS

Questions

Who owns GAMUT Therapeutics?

GAMUT Therapeutics is now owned by SparingVision, which acquired it in 2021 from AdBio Partners.

When did SparingVision acquire GAMUT Therapeutics?

SparingVision acquired GAMUT Therapeutics in 2021, buying from AdBio Partners.

Who did GAMUT Therapeutics sell to?

AdBio Partners sold GAMUT Therapeutics to SparingVision in 2021 (Trade Sale).

Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue